Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07187479

Randomized, Open Label Study to Examine Outcomes of Physiologic Insulin Resensitization in Chronic Kidney Disease and Type 2 Diabetes Mellitus

Led by Well Cell Global · Updated on 2025-10-20

120

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research evaluates Physiologic Insulin Resensitization (PIR) treatment outcomes compared to standard care in patients with chronic kidney disease (CKD) stages 3b, 4, and 5 who also have Type 2 diabetes mellitus (T2DM). The study aims to assess how PIR influences kidney function and diabetes control in this patient group. The trial is randomized and open label, led by Well Cell Global, focusing on important kidney and diabetes markers over time. Participants are divided into two groups: one receives PIR, a physician-directed treatment using an external infusion pump to deliver insulin intravenously, while the other group receives standard care without additional intervention. The study collects data at 12 and 24 weeks to compare outcomes between these approaches. Participants will attend study visits to undergo assessments including kidney function tests like estimated glomerular filtration rate (eGFR), blood urea nitrogen/creatinine ratio, cystatin C, and urine albumin-creatinine ratio. Blood tests will measure glucose control, insulin levels, blood pressure, lipid profiles, and quality of life using questionnaires. The study monitors prescribed medication usage and overall health during the 24-week period to evaluate the impact of the treatments.

CONDITIONS

Brief Title

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 or older (male or female)
  • Documented diagnosis of chronic kidney disease stage 3b, 4, or 5 and Type 2 diabetes mellitus for at least 6 months before screening
  • Stable treatment regimen for any complications for the past 6 months as judged by the investigator
  • Ability to provide informed consent, understand study procedures, and attend all required visits
  • Female participants must be either of non-childbearing potential or have a negative pregnancy test and agree to use birth control during the study
Not Eligible

You will not qualify if you...

  • Treatment for any malignancy within the past 2 years
  • Current pregnancy or intention to become pregnant during the study
  • Use of non-prescription opioids or psychoactive drugs within the past year
  • Hypoglycemic event requiring urgent care within the past 6 months unless approved by Medical Monitor
  • Participation in another clinical study involving investigational drugs or glucose control methods within the past month
  • Nursing or planning to nurse during the study
  • Positive screening test for HIV, hepatitis B surface antigen, or hepatitis C viral load
  • Abnormal laboratory results including low hemoglobin, white blood cells, platelets, or elevated liver enzymes beyond specified limits
  • Psychiatric, behavioral, cognitive, or clinical dysfunction affecting safety or compliance as assessed by investigator
  • Active dialysis treatment at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 24 weeks

Participants receive Physiologic Insulin Resensitization (PIR) treatment or standard of care to assess effects on chronic kidney disease and Type 2 diabetes mellitus.

Visits at 12 and 24 weeks for assessments

Trial Site Locations

Total: 1 location

1

Arizona Kidney Disease and Hypertension Center

Phoenix, Arizona, United States, 85027

Actively Recruiting

Loading map...

Research Team

R

Richard Marchase, PhD

S

Samantha Villaverde

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

The PILI 'Aina Project to Improve Cardiometabolic Health in...

Type 2 Diabetes

Actively Recruiting

2 locations

A Clinical Study to Evaluate the Pharmacokinetic and Pharmac...

Type 2 Diabetes

Actively Recruiting

1 location

A Feasibility Study of Optimal Non-Pharmacological Lifestyle...

Type 2 Diabetes

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here